Brief: Medicinova Announces Additional Extension Of Barda Contract To Develop Mn-166 (Ibudilast) As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury
09/03/2023 23:05
March 9 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES ADDITIONAL EXTENSION OF BARDA
CONTRACT TO
DEVELOP MN-166 (IBUDILAST) AS A MEDICAL COUNTERMEASURE AGAINST
CHLORINE GAS-INDUCED LUNG INJURY
* MEDICINOVA INC - CONTRACT WAS AMENDED TO EXTEND PERIOD OF
PERFORMANCE UNTIL MAY 31, 2023
Source text for Eikon: ID:nGNX77FZsK
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake